0001104659-24-097866.txt : 20240906
0001104659-24-097866.hdr.sgml : 20240906
20240906200213
ACCESSION NUMBER: 0001104659-24-097866
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240904
FILED AS OF DATE: 20240906
DATE AS OF CHANGE: 20240906
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HENDERSON MICHAEL THOMAS
CENTRAL INDEX KEY: 0001779990
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41740
FILM NUMBER: 241285636
MAIL ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apogee Therapeutics, Inc.
CENTRAL INDEX KEY: 0001974640
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 934958665
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 221 CRESCENT ST.
STREET 2: BUILDING 17, SUITE 102B
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 650-394-5230
MAIL ADDRESS:
STREET 1: 221 CRESCENT ST.
STREET 2: BUILDING 17, SUITE 102B
CITY: WALTHAM
STATE: MA
ZIP: 02453
FORMER COMPANY:
FORMER CONFORMED NAME: Apogee Therapeutics, LLC
DATE OF NAME CHANGE: 20230420
4
1
tm2423502-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-09-04
0
0001974640
Apogee Therapeutics, Inc.
APGE
0001779990
HENDERSON MICHAEL THOMAS
C/O APOGEE THERAPEUTICS, INC.
221 CRESCENT ST., BLDG. 17, STE. 102B
WALTHAM
MA
02453
1
1
0
0
Chief Executive Officer
1
Common Stock
2024-09-04
4
S
0
25641
47.28
D
1408846
D
Common Stock
2024-09-04
4
S
0
14359
48.23
D
1394487
D
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.
The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.95 to $47.855, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.95 to $48.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
/s/ Matthew Batters, as attorney-in-fact for Michael Henderson
2024-09-06